Summaries & Highlights
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Updates in Anal Cancer
FEATURING
Cathy Eng
- 84 views
- March 20, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Key Trial Highlights in Hepatobiliary Cancer - ACCELERATE, RACB & CheckMate 9DW
FEATURING
Richard Kim,
Tiago Biachi
- 147 views
- March 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Key Trial Highlights in mCRC and Clinical Insights
FEATURING
Richard Kim,
Tiago Biachi
- 196 views
- March 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: mCRC Case-Based Discussion - Lessons Learned
FEATURING
Rutika Mehta,
Manish A. Shah
- 228 views
- March 6, 2025
- 3
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Intermediate HCC and the Management of Liver Disease
FEATURING
Maria Reig
- 97 views
- March 4, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Development and FDA Approval of a Novel Systemic Targeted Delivery of Radiofrequency Electromagnetic Fields for Advanced R/R HCC
FEATURING
Boris Pasche
- 62 views
- February 28, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HTN, Proteinuria, Hemorrhage, and VTE in GI Cancer Patients Treated With Fruquintinib
FEATURING
Kyaw Thein
- 124 views
- February 12, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HFSR or PPE Syndrome in Patients With GI Cancers Treated With Fruquintinib
FEATURING
Kyaw Thein
- 178 views
- February 10, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Evaluating the Clinical Benefits of Anti-Cancer Drugs Approved by FDA for GI Neoplasms for the Past Two Decades
FEATURING
Fares Jamal
- 119 views
- February 10, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Incidence Trends, Demographic Disparities, and Survival Outcomes in Young Adults With Stomach and Pancreatic Cancers
FEATURING
Shivani Modi
- 20 views
- January 31, 2025
All Videos
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Neoadjuvant mFOLFIRINOX vs. Gem/nab-Paclitaxel in Borderline Resectable & Resectable Pancreatic Cancer
FEATURING
Kriti Dhamija
- 57 views
- March 28, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Ph2 INNOVATION Trial - Outcomes of Perioperative Chemo + Trastuzumab +/- Pertuzumab for 1L HER2+ Gastric/GEJ Cancer
FEATURING
Anna Dorothea Wagner
- 87 views
- March 27, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Updates in Anal Cancer
FEATURING
Cathy Eng
- 84 views
- March 20, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Alternating FOLFOX/FOLFIRI Regimen in Older Patients With Untreated Metastatic Pancreatic Cancer
FEATURING
Arthur Winer
- 118 views
- March 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Key Trial Highlights in Hepatobiliary Cancer - ACCELERATE, RACB & CheckMate 9DW
FEATURING
Richard Kim,
Tiago Biachi
- 147 views
- March 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Key Trial Highlights in mCRC and Clinical Insights
FEATURING
Richard Kim,
Tiago Biachi
- 196 views
- March 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: mCRC Case-Based Discussion - Lessons Learned
FEATURING
Rutika Mehta,
Manish A. Shah
- 228 views
- March 6, 2025
- 3
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Latest Targeted Therapy Highlights in Advanced Biliary Tract Cancers
FEATURING
James Harding
- 53 views
- March 4, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Intermediate HCC and the Management of Liver Disease
FEATURING
Maria Reig
- 97 views
- March 4, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Expression of Metabolic Genes Affects Patient Outcomes in mCRC - Data From CALGB/SWOG 80405 (Alliance)
FEATURING
Francesca Battaglin
- 40 views
- March 4, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Adagrasib + Cetuximab for KRAS G12C-Mutated mCRC - KRYSTAL-1 Trial Longer Follow-Up Analysis
FEATURING
Rona Yaeger
- 44 views
- March 4, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Development and FDA Approval of a Novel Systemic Targeted Delivery of Radiofrequency Electromagnetic Fields for Advanced R/R HCC
FEATURING
Boris Pasche
- 62 views
- February 28, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Camrelizumab + Rivoceranib vs. Sorafenib for 1L Unresectable HCC of Viral and Non-Viral Etiology - Ph3 CARES-310 Trial
FEATURING
Rachna Shroff
- 65 views
- February 25, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Appendix Cancer - Not Just Appendicitis Anymore
FEATURING
Perry Shen
- 121 views
- February 25, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Real-World Evidence of Nanoliposomal Irinotecan + 5FU + Leucovorin in Unresectable or Recurrent Pancreatic Cancer - NAPOLEON-2 Study
FEATURING
Tsuyoshi Shirakawa
- 116 views
- February 21, 2025
- 3
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuximab + Chemo in 1L BRAF V600E-Mutant mCRC
FEATURING
Scott Kopetz
- 282 views
- February 19, 2025
- 2
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Preliminary Safety and Efficacy of Upfront FOLFOXIRI + Bevacizumab + Cadonilimab in pMMR/MSS mCRC - Ph2 SYLT-026 Study
FEATURING
Rongbo Lin
- 51 views
- February 18, 2025
Insights from 2024 ESMO GI Annual Meeting
ESMO GI 2024 & ASCO® GI 2025 Insights: Cabozantinib vs. Placebo for R/R Advanced NET - Updated Results From the Ph3 CABINET Trial
FEATURING
Shagufta Shaheen
- 73 views
- February 18, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Precision Medicine and Multidisciplinary Care in GC/GEJC - Challenges and Practice Gaps in Community Cancer Clinics
FEATURING
Matthew Strickland
- 74 views
- February 18, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Safety, Efficacy, and ctDNA Changes of RMC-6236, a RAS(ON) Multi-Selective Inhibitor, in R/R RAS-Mutant PDAC
FEATURING
Ignacio Garrido-Laguna
- 72 views
- February 18, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: NRG-GI007 Trial - Final Safety Assessment & cCR Rate of CRT With Endoscopically Injected Oncolytic Virus OBP-301 in Medically Inoperable Esophageal Cancer
FEATURING
Geoffrey Ku
- 88 views
- February 14, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Uses of Bevacizumab in Appendiceal Adenocarcinoma
FEATURING
John Shen
- 152 views
- February 12, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Pt Characteristics, Treatment Patterns, and Survival Outcomes in Unresectable HCC Treated With 1L Systemic Therapy in the US
FEATURING
Nguyen Tran
- 82 views
- February 12, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HTN, Proteinuria, Hemorrhage, and VTE in GI Cancer Patients Treated With Fruquintinib
FEATURING
Kyaw Thein
- 124 views
- February 12, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HFSR or PPE Syndrome in Patients With GI Cancers Treated With Fruquintinib
FEATURING
Kyaw Thein
- 178 views
- February 10, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Evaluating the Clinical Benefits of Anti-Cancer Drugs Approved by FDA for GI Neoplasms for the Past Two Decades
FEATURING
Fares Jamal
- 119 views
- February 10, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Trifluridine/Tipiracil vs. Placebo in Patients With Molecular Residual Disease Following Curative Resection of CRC - Ph3 ALTAIR Study
FEATURING
Hideaki Bando
- 159 views
- February 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Serum MUC5AC as a Predictor of Outcomes and Microscopic Metastasis in PDAC
FEATURING
Ashish Manne
- 119 views
- February 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Geriatric and QoL Assessments on Gem/Nab-Pac vs. 5-FU/Leucovorin/Liposomal Irinotecan in Older Patients With mPDAC - GIANT Study Results
FEATURING
Efrat Dotan
- 62 views
- February 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Preoperative Botensilimab +/- Balstilimab in Resectable Locally Advanced pMMR/dMMR CRC - UNICORN Trial Results
FEATURING
Filippo Ghelardi
- 96 views
- February 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Unlocking the Potential of ADCs in Pancreaticobiliary Cancers - Mechanisms and Key Selection Criteria
FEATURING
Lei Zheng
- 133 views
- February 7, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Biomarker-Based Interception of Esophageal Adenocarcinoma
FEATURING
Sanford Markowitz
- 94 views
- February 6, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Real-World Experience With Atezo + Bev in Unresectable HCC - A Multicenter Study
FEATURING
Maen Abdelrahim
- 191 views
- February 6, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Impact of UGT1A1*28 Polymorphism on Treatment Tolerability in mPDAC Patients Receiving NALIRIFOX - NAPOLI-3 Trial
FEATURING
Maen Abdelrahim
- 184 views
- February 6, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Real-World Genomic Testing Performance in CRC - The MultiTEAM Systems Framework Precision Oncology Reflex Testing (TEAMSPORT)
FEATURING
Haoran Li
- 44 views
- February 5, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Real-World Outcomes of Durvalumab +/- Tremelimumab in Unresectable HCC - Preliminary Results From the International DT-Real Study
FEATURING
Ciro Celsa
- 92 views
- February 4, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Encorafenib + Cetuximab +/- Binimetinib in BRAF-Mutated mCRC With Prognostic Factors - The BEETS Trial (JACCRO CC-18)
FEATURING
Yu Sunakawa
- 160 views
- February 4, 2025
- 2
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: CheckMate 8HW - First Results of Nivo + Ipi vs. Nivo in MSI-H/dMMR mCRC
FEATURING
Thierry André
- 275 views
- February 4, 2025
- 1
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Ph2 Study of Neoadjuvant FLOT for Resectable ESCC
FEATURING
Shun Yamamoto
- 131 views
- February 3, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: Phase 1b Study of Gemcitabine & Nab-Paclitaxel in Combination With Lixumistat for Treatment-Naïve mPDAC
FEATURING
Shubham Pant
- 101 views
- February 3, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Summary: Incidence Trends, Demographic Disparities, and Survival Outcomes in Young Adults With Stomach and Pancreatic Cancers
FEATURING
Shivani Modi
- 20 views
- January 31, 2025
Insights from 2025 ASCO® GI Annual Meeting
ASCO® GI 2025 Insights: mFOLFIRINOX Efficacy in First and Subsequent Lines for Advanced GEP NETs
FEATURING
Yaroslav Zhulikov,
Ekaterina Evdokimova
- 200 views
- January 31, 2025
- 3